<p>2025 年 7 月 11 日- 下午 4:21</p>
<p><em>特别会议有效地延期，直到适当的法院对 PIPE 股份的有效性做出最终裁决，并将重新召开</em></p>
<p><em>SAIF 和反对投资者集团关于 “继续特别会议” 和假装的 “董事会” 的欺骗性声明是虚假的，毫无法律依据</em></p>
<p><em>当前董事会仍然是 SINOVAC 唯一有效的董事会，并将继续管理公司</em></p>
<p>北京 --（商业资讯）--SINOVAC 生物科技有限公司（NASDAQ: SVA）（“SINOVAC” 或 “公司”）的董事会今天发布以下更新，以澄清有关股东特别会议（“特别会议”）的记录：</p>
<ul>
<li><strong>特别会议于 2025 年 7 月 8 日由 SINOVAC 董事长 Chiang Li 有效地延期</strong>，原因是关于在安提瓜进行的诉讼，涉及据称在对 Advantech/Prime 和 Vivo Capital（统称为 “反对投资者集团”）进行无效的私募股权投资后发行的股份的有效性。独立选举监察员已承认该延期，并拥有唯一的权力宣布和认证特别会议的结果。</li>
<li><strong>SAIF 关于 “继续特别会议” 的虚假声明是故意误导的，并且在公司的章程和安提瓜法律下完全非法。</strong> 在特别会议有效延期并且虚拟会议终止后，代表 SAIF 和反对投资者集团的一组律师自称在未宣布的地点和时间组织了一次无效的假装特别会议。该小组没有提前通知有效股东或给予他们参加的选择，也没有联系 SINOVAC 董事长 Chiang Li，后者是特别会议的唯一授权主席。没有选举监察员主持假装的特别会议。当前的 SINOVAC 董事会了解到，Mr. Yuk Lam Lo 参加了无效会议，并理解他没有权力主持任何此类股东会议。在假装的特别会议上，该小组宣布了来自未进行的 “投票” 的假装 “投票结果”，因为有效的延期导致投票未能进行。次日，SAIF 和反对投资者集团召开了一次假装会议，选举了一位假装的主席。有效的 SINOVAC 股东被告诫忽略这些戏剧。董事会由 Dr. Chiang Li（主席）、Mr. Yuk Lam Lo、Mr. Sven Borho 和 Mr. Geoffrey Hsu 组成，保留全面管理 SINOVAC 的权力。假装董事会的任何流氓行为都是无效或非法的。SAIF 和反对投资者集团将对此负责。</li>
<li><strong>在特别会议召开时，安提瓜和巴布达东加勒比最高法院（“安提瓜高等法院”）于 2025 年 7 月 7 日授予的禁令——禁止 PIPE 股份在会议上投票——尚未被推翻。</strong> 虽然东加勒比上诉法院暂时暂停了禁令，但该暂停将持续到举行听证会以确定是否应授予该暂停。2025 年 7 月 11 日，安提瓜高等法院的法官 Bakre 作出裁决，表示授予暂停将使本案变成 “笑话”。</li>
<li><strong>安提瓜正在进行的法律程序以确定 PIPE 股份的有效性。当前董事会将在适当法院解决此问题后重新召开特别会议。在此期间，投票不可用。</strong> 所有有效股东的投票将在有效重新召开的特别会议上被计算。</li>
<li><strong>当前的 SINOVAC 董事会仍然在位，正在管理公司，</strong> <strong>并在执行其既定优先事项。</strong> 这些包括根据其先前宣布的政策进行股息分配，以及自 2025 年 7 月 7 日起向有效股东或其经纪人支付每普通股 55.00 美元的特别现金股息，努力与 NASDAQ 恢复交易，任命新的审计师，以及探索未来在香港证券交易所上市以促进流动性和最大化价值创造。</li>
</ul>
<p><strong>SINOVAC 董事会敦促所有股东仅依赖合法董事会的官方通讯以获取准确信息。董事会致力于透明度和法治，并将在事态发展时提供进一步更新。</strong></p>
<p>有关持续更新和更多信息，请访问 www.votesinovac.com。</p>
<p><strong>关于 SINOVAC</strong></p>
<p>SINOVAC 生物科技有限公司（SINOVAC）是一家总部位于中国的生物制药公司，专注于研发、生产和商业化保护人类免疫疾病的疫苗。</p>
<p>SINOVAC 的产品组合包括针对 COVID-19、71 型肠病毒（EV71）感染的手足口病（HFMD）、甲型肝炎、水痘、流感、小儿麻痹症、肺炎球菌疾病等的疫苗。</p>
<p>COVID-19 疫苗 CoronaVac®已在全球 60 多个国家和地区获得使用批准。甲型肝炎疫苗 Healive®于 2017 年通过了世界卫生组织的预认证要求。EV71 疫苗 Inlive®是一种创新疫苗，属于 “第一类预防性生物制品”，并于 2016 年在中国商业化。2022 年，SINOVAC 的 Sabin 株灭活脊髓灰质炎疫苗（sIPV）和水痘疫苗获得了世界卫生组织的预认证。</p>
<p>SINOVAC 是首家获得 H1N1 流感疫苗 Panflu.1®批准的公司，该疫苗已为中国政府的疫苗接种运动和储备计划提供了供应。该公司也是中国政府储备计划中 H5N1 大流行流感疫苗 Panflu®的唯一供应商。</p>
<p>科兴生物持续致力于新疫苗的研发，管道中有更多组合疫苗产品，并不断探索全球市场机会。科兴生物计划与更多国家及商业和行业组织进行更广泛和深入的贸易与合作。</p>
<p><strong>重要附加信息及获取途径</strong></p>
<p>关于科兴生物的特别会议，科兴生物已向美国证券交易委员会（“SEC”）提交文件，并向有权在特别会议上投票的股东邮寄了最终代理声明及其他文件，包括一张白色代理卡。鼓励股东在与 SEC 提交并可用时阅读代理声明及所有其他相关文件，因为这些文件将包含重要信息。投资者和其他相关方可以在 SEC 的网站 www.sec.gov 上免费获取这些文件，或从科兴生物的网站 https://www.sinovac.com/en-us/Investors/sec_filings 获取。您也可以通过联系科兴生物的投资者关系部门 ir@sinovac.com 免费获取科兴生物的最终代理声明及其他文件的副本。</p>
<p><strong>安全港声明</strong></p>
<p>本公告包含根据 1934 年证券交易法第 21E 条及 1995 年美国私人证券诉讼改革法案的定义的前瞻性声明。这些前瞻性声明可以通过诸如 “可能”、“将”、“期望”、“预期”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能” 等类似术语识别。这些声明基于当前的预期和市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测，并且许多因素超出了公司或董事会的控制，可能导致实际结果、表现或成就与前瞻性声明中的内容有重大差异。有关这些及其他风险、不确定性或因素的进一步信息包含在公司向美国证券交易委员会的文件中。公司和董事会不承担因新信息、未来事件或其他原因更新任何前瞻性声明的义务，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MTExODg0NDhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MTExODg0NDhyMQ"/></p>
<p>查看商业电讯上的源版本：https://www.businesswire.com/news/home/20250711188448/en/</p>
<p><strong>投资者和媒体联系</strong></p>
<p>FGS Global</p>
<p>Sinovac@fgsglobal.com</p>
<p>来源：科兴生物科技有限公司董事会</p>

<p>SINOVAC 生物科技有限公司宣布，其于 2025 年 7 月 8 日召开的特别股东会议因关于 PIPE 股份有效性的持续诉讼而有效地延期。由董事长蒋立领导的现任董事会仍然是唯一有效的管理机构，驳斥了 SAIF 和反对投资者集团的主张，称其具有误导性。董事会将在法律问题解决后重新召开会议，合法股东的投票将被计算在内。公司继续执行其优先事项，包括分红分配和探索未来在香港证券交易所上市的可能性</p>

<p>07/11/2025 - 04:21 PM</p>
<div class="lb-trans"><p>2025 年 7 月 11 日- 下午 4:21</p>
</div><p><em>Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened</em></p>
<div class="lb-trans"><p><em>特别会议有效地延期，直到适当的法院对 PIPE 股份的有效性做出最终裁决，并将重新召开</em></p>
</div><p><em>SAIF and the Dissenting Investor Group’s deceptive claims of a “continuation of the Special Meeting” and a pretend “Board” are fake and without legal basis</em></p>
<div class="lb-trans"><p><em>SAIF 和反对投资者集团关于 “继续特别会议” 和假装的 “董事会” 的欺骗性声明是虚假的，毫无法律依据</em></p>
</div><p><em>Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company</em></p>
<div class="lb-trans"><p><em>当前董事会仍然是 SINOVAC 唯一有效的董事会，并将继续管理公司</em></p>
</div><p>BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the “Special Meeting”):</p>
<div class="lb-trans"><p>北京 --（商业资讯）--SINOVAC 生物科技有限公司（NASDAQ: SVA）（“SINOVAC” 或 “公司”）的董事会今天发布以下更新，以澄清有关股东特别会议（“特别会议”）的记录：</p>
</div><ul>
<li><strong>The Special Meeting was validly adjourned</strong> by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity (“PIPE”) to Advantech/Prime and Vivo Capital (together known as the “Dissenting Investor Group”). The adjournment has been recognized by the independent Inspector of Elections who has the sole authority to announce and certify the results of the Special Meeting.</li>
<li><strong>SAIF’s false claim that a “continuation of the Special Meeting” occurred is intentionally deceptive and entirely illegal under the Company’s bylaws and Antiguan law.</strong> Immediately after the Special Meeting was validly adjourned and the virtual meeting was terminated, a group of lawyers representing SAIF and the Dissenting Investor Group purportedly self-organized an invalid, pretend special meeting at an unannounced location and time. This group did not give advance notice to valid shareholders or give them an option to attend, and they did not contact SINOVAC Chairman Chiang Li, the only authorized chair for the Special Meeting. No inspector of elections presided over the pretend special meeting. The current SINOVAC Board understands Mr. Yuk Lam Lo attended the invalid meeting with the understanding that he had no authority to chair any such shareholder meeting. At the pretend special meeting, this group announced pretend “voting results” from a “vote” that did not take place due to the valid adjournment. The following day, SAIF and the Dissenting Investor Group held a pretend meeting to elect a pretend Chairman. Valid SINOVAC shareholders are admonished to ignore these theatrics. The Board, consisting of Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven Borho and Mr. Geoffrey Hsu, retains full authority to run SINOVAC. None of the pretend board’s rogue actions are valid or legal. SAIF and the Dissenting Investor Group will be held responsible.</li>
<li><strong>At the time of the Special Meeting, the injunction granted by the Eastern Caribbean Supreme Court of Antigua and Barbuda (the “Antigua High Court”) on July 7, 2025 – prohibiting the PIPE shares from voting at the meeting – had not been overturned.</strong> While the Eastern Caribbean Court of Appeal temporarily stayed the injunction order, the stay is in place until a hearing is held to determine whether such stay should have been granted. On July 11, 2025, Judge Bakre of the Antigua High Court issued a ruling, which stated that granting a stay would make a “mockery” of this case.</li>
<li><strong>There are ongoing legal proceedings in Antigua to determine the validity of the PIPE shares. The current Board will reconvene the Special Meeting once this issue is resolved by the proper court. During this period, voting is unavailable.</strong> All valid shareholders will have their vote counted at the validly reconvened Special Meeting.</li>
<li><strong>The current SINOVAC Board remains in place, is governing the Company,</strong> <strong>and is executing on its stated priorities.</strong> These includedividend distributions according to its previously announced policy, in addition to the ongoing payment of the US$55.00 per common share special cash dividend paid to valid shareholders or their brokers beginning on July 7, 2025, working with NASDAQ to resume trading, the appointment of a new auditor, and exploring a future listing on the Stock Exchange of Hong Kong to promote liquidity and maximize value creation.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>特别会议于 2025 年 7 月 8 日由 SINOVAC 董事长 Chiang Li 有效地延期</strong>，原因是关于在安提瓜进行的诉讼，涉及据称在对 Advantech/Prime 和 Vivo Capital（统称为 “反对投资者集团”）进行无效的私募股权投资后发行的股份的有效性。独立选举监察员已承认该延期，并拥有唯一的权力宣布和认证特别会议的结果。</li>
<li><strong>SAIF 关于 “继续特别会议” 的虚假声明是故意误导的，并且在公司的章程和安提瓜法律下完全非法。</strong> 在特别会议有效延期并且虚拟会议终止后，代表 SAIF 和反对投资者集团的一组律师自称在未宣布的地点和时间组织了一次无效的假装特别会议。该小组没有提前通知有效股东或给予他们参加的选择，也没有联系 SINOVAC 董事长 Chiang Li，后者是特别会议的唯一授权主席。没有选举监察员主持假装的特别会议。当前的 SINOVAC 董事会了解到，Mr. Yuk Lam Lo 参加了无效会议，并理解他没有权力主持任何此类股东会议。在假装的特别会议上，该小组宣布了来自未进行的 “投票” 的假装 “投票结果”，因为有效的延期导致投票未能进行。次日，SAIF 和反对投资者集团召开了一次假装会议，选举了一位假装的主席。有效的 SINOVAC 股东被告诫忽略这些戏剧。董事会由 Dr. Chiang Li（主席）、Mr. Yuk Lam Lo、Mr. Sven Borho 和 Mr. Geoffrey Hsu 组成，保留全面管理 SINOVAC 的权力。假装董事会的任何流氓行为都是无效或非法的。SAIF 和反对投资者集团将对此负责。</li>
<li><strong>在特别会议召开时，安提瓜和巴布达东加勒比最高法院（“安提瓜高等法院”）于 2025 年 7 月 7 日授予的禁令——禁止 PIPE 股份在会议上投票——尚未被推翻。</strong> 虽然东加勒比上诉法院暂时暂停了禁令，但该暂停将持续到举行听证会以确定是否应授予该暂停。2025 年 7 月 11 日，安提瓜高等法院的法官 Bakre 作出裁决，表示授予暂停将使本案变成 “笑话”。</li>
<li><strong>安提瓜正在进行的法律程序以确定 PIPE 股份的有效性。当前董事会将在适当法院解决此问题后重新召开特别会议。在此期间，投票不可用。</strong> 所有有效股东的投票将在有效重新召开的特别会议上被计算。</li>
<li><strong>当前的 SINOVAC 董事会仍然在位，正在管理公司，</strong> <strong>并在执行其既定优先事项。</strong> 这些包括根据其先前宣布的政策进行股息分配，以及自 2025 年 7 月 7 日起向有效股东或其经纪人支付每普通股 55.00 美元的特别现金股息，努力与 NASDAQ 恢复交易，任命新的审计师，以及探索未来在香港证券交易所上市以促进流动性和最大化价值创造。</li>
</ul>
</div><p><strong>The SINOVAC Board urges all shareholders to rely only on official communications from the rightful Board for accurate information. The Board remains committed to transparency and the rule of law and will provide further updates as developments occur.</strong></p>
<div class="lb-trans"><p><strong>SINOVAC 董事会敦促所有股东仅依赖合法董事会的官方通讯以获取准确信息。董事会致力于透明度和法治，并将在事态发展时提供进一步更新。</strong></p>
</div><p>For ongoing updates and further information, please visit www.votesinovac.com.</p>
<div class="lb-trans"><p>有关持续更新和更多信息，请访问 www.votesinovac.com。</p>
</div><p><strong>About SINOVAC</strong></p>
<div class="lb-trans"><p><strong>关于 SINOVAC</strong></p>
</div><p>Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&amp;D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.</p>
<div class="lb-trans"><p>SINOVAC 生物科技有限公司（SINOVAC）是一家总部位于中国的生物制药公司，专注于研发、生产和商业化保护人类免疫疾病的疫苗。</p>
</div><p>SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.</p>
<div class="lb-trans"><p>SINOVAC 的产品组合包括针对 COVID-19、71 型肠病毒（EV71）感染的手足口病（HFMD）、甲型肝炎、水痘、流感、小儿麻痹症、肺炎球菌疾病等的疫苗。</p>
</div><p>The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under &#34;Category 1 Preventative Biological Products&#34; and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.</p>
<div class="lb-trans"><p>COVID-19 疫苗 CoronaVac®已在全球 60 多个国家和地区获得使用批准。甲型肝炎疫苗 Healive®于 2017 年通过了世界卫生组织的预认证要求。EV71 疫苗 Inlive®是一种创新疫苗，属于 “第一类预防性生物制品”，并于 2016 年在中国商业化。2022 年，SINOVAC 的 Sabin 株灭活脊髓灰质炎疫苗（sIPV）和水痘疫苗获得了世界卫生组织的预认证。</p>
</div><p>SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.</p>
<div class="lb-trans"><p>SINOVAC 是首家获得 H1N1 流感疫苗 Panflu.1®批准的公司，该疫苗已为中国政府的疫苗接种运动和储备计划提供了供应。该公司也是中国政府储备计划中 H5N1 大流行流感疫苗 Panflu®的唯一供应商。</p>
</div><p>SINOVAC continually dedicates itself to new vaccine R&amp;D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.</p>
<div class="lb-trans"><p>科兴生物持续致力于新疫苗的研发，管道中有更多组合疫苗产品，并不断探索全球市场机会。科兴生物计划与更多国家及商业和行业组织进行更广泛和深入的贸易与合作。</p>
</div><p><strong>Important Additional Information and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>重要附加信息及获取途径</strong></p>
</div><p>In connection with SINOVAC’s Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission (“SEC”) and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from SINOVAC at its website: https://www.sinovac.com/en-us/Investors/sec_filings. You may also obtain copies of SINOVAC’s definitive proxy statement and other documents, free of charge, by contacting SINOVAC’s Investor Relations Department at ir@sinovac.com.</p>
<div class="lb-trans"><p>关于科兴生物的特别会议，科兴生物已向美国证券交易委员会（“SEC”）提交文件，并向有权在特别会议上投票的股东邮寄了最终代理声明及其他文件，包括一张白色代理卡。鼓励股东在与 SEC 提交并可用时阅读代理声明及所有其他相关文件，因为这些文件将包含重要信息。投资者和其他相关方可以在 SEC 的网站 www.sec.gov 上免费获取这些文件，或从科兴生物的网站 https://www.sinovac.com/en-us/Investors/sec_filings 获取。您也可以通过联系科兴生物的投资者关系部门 ir@sinovac.com 免费获取科兴生物的最终代理声明及其他文件的副本。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.</p>
<div class="lb-trans"><p>本公告包含根据 1934 年证券交易法第 21E 条及 1995 年美国私人证券诉讼改革法案的定义的前瞻性声明。这些前瞻性声明可以通过诸如 “可能”、“将”、“期望”、“预期”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能” 等类似术语识别。这些声明基于当前的预期和市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测，并且许多因素超出了公司或董事会的控制，可能导致实际结果、表现或成就与前瞻性声明中的内容有重大差异。有关这些及其他风险、不确定性或因素的进一步信息包含在公司向美国证券交易委员会的文件中。公司和董事会不承担因新信息、未来事件或其他原因更新任何前瞻性声明的义务，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MTExODg0NDhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250711188448r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250711188448/en/</p>
<div class="lb-trans"><p>查看商业电讯上的源版本：https://www.businesswire.com/news/home/20250711188448/en/</p>
</div><p><strong>Investor and Media Contact</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系</strong></p>
</div><p>FGS Global</p>
<div class="lb-trans"><p>FGS Global</p>
</div><p>Sinovac@fgsglobal.com</p>
<div class="lb-trans"><p>Sinovac@fgsglobal.com</p>
</div><p>Source: The Board of Directors of Sinovac Biotech Ltd.</p>
<div class="lb-trans"><p>来源：科兴生物科技有限公司董事会</p>
</div>

科兴控股董事会就 7 月 8 日股东特别会议澄清事实 | SVA 股票新闻